Med Tech-related technology assessments and clinical guidelines from NICE in August 2018

02

Nov 2018

Interventional Procedure Guidance is developed for most of the novel interventional procedures entering the English market. The program focuses solely on the clinical evidence. Recommendations may vary from ‘for research only’ to ‘for use with standard arrangements for clinical governance, consent, and audit.' Recommendations are not binding, although they are followed by providers and commissioners.

In August NICE published four new Interventional Procedure Guidance:

  • Interventional Procedure Guidance Leadless cardiac pacemaker implantation for bradyarrhythmias, which covers evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. Evidence on the safety of shows that there are serious but well-recognised complications. The evidence on efficacy is inadequate in quantity and quality. For people who can have conventional cardiac pacemaker implantation, leadless pacemakers should only be used in the context of research. For people in whom a conventional cardiac pacemaker implantation is contraindicated following a careful risk assessment by a multidisciplinary team, leadless cardiac pacemakers should only be used with special arrangements for clinical governance, consent and audit or research.
  • Interventional Procedure Guidance Superior rectal artery embolisation for haemorrhoids, which covers evidence-based recommendations on blocking the blood vessels supplying the haemorrhoids with tiny plastic particles or metal coils. Current evidence on the safety and efficacy of superior rectal artery embolisation for haemorrhoids is inadequate in quality and quantity. Therefore, this procedure should only be used in the context of research.
  • Interventional Procedure Guidance Sutureless aortic valve replacement for aortic stenosis, which covers evidence-based recommendations on removing the narrowed aortic valve and replacing it with an artificial valve that holds itself in place for aortic stenosis in adults. Current evidence on the safety and efficacy of sutureless aortic valve replacement for aortic stenosis is adequate to support the use of this procedure, provided that standard arrangements are in place for clinical governance, consent and audit.
  • Interventional Procedure Guidance Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia, which covers evidence-based recommendations on using heated water vapour to destroy some of the prostate tissue for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. Current evidence on the safety and efficacy of transurethral water vapour ablation for urinary tract symptoms caused by benign prostatic hyperplasia is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.

MedTech Innovation Briefing is the NICE's advice program for innovative technologies. It provides an overview of clinical effectiveness, safety and cost. It does not offer a formal guidance, and it, therefore, does not provide any recommendations.

Four new Medtech Innovation Briefings for Rezum for treating benign prostatic hyperplasia (device uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benign prostatic hyperplasia), AlignRT in breast cancer radiotherapy (patient position monitoring system for breast cancer radiation therapy), NephroCheck test to help assess the risk of acute kidney injury in critically ill patients (in vitro diagnostic test used to measure urinary biomarkers of kidney injury as an aid in detecting acute kidney injury) and Neon EEG electrode for EEG monitoring in newborns (EEG electrode used for electroencephalogram (EEG) monitoring in newborns) have been published in August.

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

01

Dec 2022

In November 2022, NHS Accelerated Access Collaborative decided not to add new technologies to MedTech Funding Mandate (MTFM) in 2023/24. Instead, Integrated Care Systems (ICSs) are asked to prioritize the appropriate adoption of currently supported technologies where this has not yet occurred. The MTFM supports eleven NICE-approved and cost-saving devices, diagnostics, and digital products, making them mandatory for implementation and funding.

Read more

24

Nov 2022

In November 2022, NHS Digital published a final summary of core changes from OPCS-4.9 to OPCS-4.10 to be introduced from April 01, 2023. OPCS-4 is a statistical classification for clinical coding of interventions and procedures undertaken within the NHS. It is updated every three years. A total of 236 new four-character codes will be implemented in OPCS-4.10. Key changes concern cardiovascular, gastrointestinal, endoscopy, ENT, nephrology and urology, neurology and neurosurgery, obstetrics and gynecology, orthopedic, and breast surgery fields.

Read more

23

Nov 2022

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 21738 of November 4, 2022, Tuscany Regional Healthcare has published assessments of three medical devices in the orthopedics, surgical procedures, and peripheral vascular areas.

Read more

21

Nov 2022

In November 2022, NHS England defined a deadline for applications to the High Cost Device List (HCDL) changes to be implemented in the 2024/25 National Tariff Payment System. The completed application form should be submitted via email by May 31, 2023.

Read more

11

Nov 2022

MedTech-related health technology assessments from NIHR in October 2022
In October 2022, the National Institute for Health and Care Research (NIHR) in England released one MedTech-related report in its Health Technology Assessment (HTA) Journal, which concerned photodynamic versus white-light-guided resection of non-muscle-invasive bladder cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more